查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1448590

全球活性藥物成分 CDMO 市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢與預測

Global Active Pharmaceutical Ingredient CDMO Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032
出版日期: | 出版商: Value Market Research | 英文 220 Pages | 商品交期: 最快1-2個工作天內

價格

全球活性藥物成分CDMO市場需求預計將從2023年的1,023億美元達到2032年近2,072.4億美元的市場規模，2024-2032年研究期間的CAGR為8.16%。

活性藥物成分合約開發和製造組織 (API CDMO) 專門從事活性藥物成分的開發和生產，活性藥物成分是藥物中的生物活性成分。這些組織提供從研發到大規模製造的服務，為製藥公司提供專業知識和基礎設施，以將藥物高效推向市場並符合監管標準。

市場動態

活性藥物成分 (API) 合約開發和製造組織市場是由藥物開發日益複雜、製藥業的外包趨勢以及對具有成本效益和靈活的製造解決方案的需求等因素推動的。製藥公司正在轉向 API CDMO，以利用他們在開發和生產高品質活性藥物成分方面的專業知識。生物製藥和特殊藥物數量的不斷增加，加上對專業製造能力的需求，促進了市場的成長。 API CDMO 具有縮短上市時間、取得先進技術以及降低藥物開發風險等優勢。個人化醫療的趨勢和不斷成長的創新療法管道也增加了對 API CDMO 服務的需求。監管要求和遵守良好生產規範 (GMP) 標準的需要促使製藥公司與專門的 API CDMO 合作，促進藥物開發的創新和效率。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球活性藥物成分 cdmo 市場的各個細分市場進行了包容性評估。活性藥物成分 cdmo 產業的成長和趨勢為本研究提供了整體方法。

市場區隔

活性藥物成分 cdmo 市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助策略師確定相應產品或服務的目標人群以及即將到來的機會。

按產品分類

  • 傳統活性藥物成分（傳統 Api）
  • 高效活性藥物成分 (Hp-Api)
  • 抗體藥物偶聯物 (Adc)
  • 其他

透過合成

  • 合成的
  • 生物技術

按藥物分類

  • 創新的
  • 泛型

按工作流程

  • 臨床
  • 商業的

按應用

  • 腫瘤學
  • 荷爾蒙
  • 青光眼
  • 心血管疾病
  • 糖尿病
  • 其他

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲活性藥物成分 CDMO 市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。活性藥物成分 CDMO 市場的主要參與者包括 Cambrex Corporation、Recipharm AB、Thermo Fisher Scientific Inc. (Pantheon)、CordenPharma International、Samsung Biologics、Lonza、Catalent, Inc.、Siegfried Holding AG、Piramal Pharma Solutions、Boehringer Ingelheim International有限公司。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

目錄

第1章：前言

  • 報告說明
    • 客觀的
    • 目標受眾
    • 獨特的銷售主張 (USP) 和產品
  • 研究範圍
  • 研究方法論
    • 市場研究過程
    • 市場研究方法論

第 2 章：執行摘要

  • 市場亮點
  • 全球市場概況

第 3 章：活性藥物成分 CDMO - 產業分析

  • 簡介 - 市場動態
  • 市場促進因素
  • 市場限制
  • 機會
  • 產業動態
  • 波特五力分析
  • 市場吸引力分析
    • 按產品分類的市場吸引力分析
    • 市場吸引力綜合分析
    • 藥品市場吸引力分析
    • 依工作流程進行市場吸引力分析
    • 市場吸引力分析：依應用分類
    • 市場吸引力分析：按地區

第 4 章：價值鏈分析

  • 價值鏈分析
  • 原料分析
    • 原料清單
    • 原料廠商清單
    • 主要原物料價格走勢
  • 潛在買家名單
  • 行銷管道
    • 直效行銷
    • 間接行銷
    • 行銷通路發展趨勢

第 5 章：全球活性藥物成分 CDMO 市場分析：依產品

  • 按產品概述
  • 歷史和預測數據
  • 按產品分析
  • 傳統活性藥物成分（傳統 API）
  • 高效活性藥物成分 (HP-API)
  • 抗體藥物偶聯物 (ADC)
  • 其他

第 6 章：全球活性藥物成分 CDMO 市場分析：綜合分析

  • 綜合概述
  • 歷史和預測數據
  • 綜合分析
  • 合成的
  • 生物技術

第 7 章：全球活性藥物成分 CDMO 市場分析：依藥物分類

  • 按藥物概述
  • 歷史和預測數據
  • 藥物分析
  • 創新的
  • 泛型

第 8 章：全球活性藥物成分 CDMO 市場分析：依工作流程

  • 按工作流程概述
  • 歷史和預測數據
  • 按工作流程分析
  • 臨床
  • 商業的

第 9 章：全球活性藥物成分 CDMO 市場分析：依應用分類

  • 概述：按應用
  • 歷史和預測數據
  • 分析：按應用
  • 腫瘤學
  • 荷爾蒙
  • 青光眼
  • 心血管疾病
  • 糖尿病
  • 其他

第 10 章：全球活性藥物成分 CDMO 市場分析：依地理位置

  • 區域展望
  • 介紹
  • 北美銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 北美按細分市場銷售分析
    • 北美按國家銷售分析
    • 美國銷售分析
    • 加拿大銷售分析
    • 墨西哥銷售分析
  • 歐洲銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 歐洲按細分市場銷售分析
    • 歐洲按國家銷售分析
    • 英國銷售分析
    • 法國銷售分析
    • 德國銷售分析
    • 義大利銷售分析
    • 俄羅斯銷售分析
    • 歐洲其他地區銷售分析
  • 亞太地區銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 亞太地區按細分市場銷售分析
    • 亞太地區國家/地區銷售分析
    • 中國銷售分析
    • 印度銷售分析
    • 日本銷售分析
    • 韓國銷售分析
    • 澳洲銷售分析
    • 東南亞銷售分析
    • 亞太地區其他地區銷售分析
  • 拉丁美洲銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 拉丁美洲按細分市場銷售分析
    • 拉丁美洲按國家銷售分析
    • 巴西銷售分析
    • 阿根廷銷售分析
    • 秘魯銷售分析
    • 智利銷售分析
    • 拉丁美洲其他地區銷售分析
  • 中東和非洲銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 中東和非洲按細分市場銷售分析
    • 中東和非洲國家銷售分析
    • 沙烏地阿拉伯銷售分析
    • 阿拉伯聯合大公國銷售分析
    • 以色列銷售分析
    • 南非銷售分析
    • 中東其他地區和非洲銷售分析

第 11 章：活性藥物成分 CDMO 公司的競爭格局

  • 活性藥物成分Cdmo市場競爭
  • 夥伴關係/協作/協議
  • 併購
  • 新產品發布
  • 其他發展

第 12 章：公司簡介

  • 公司股份分析
  • 市場集中度
  • Cambrex Corporation
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Recipharm AB
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Thermo Fisher Scientific Inc. (Pantheon)
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • CordenPharma International
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Samsung Biologics
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Lonza
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Catalent Inc.
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Siegfried Holding AG
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Piramal Pharma Solutions
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Boehringer Ingelheim International GmbH
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展

注意 - 在公司概況中，財務詳細資訊和近期發展視情況而定，或者如果是私人公司，則可能不包括在內

Product Code: VMR112113753

The global demand for Active Pharmaceutical Ingredient CDMO Market is presumed to reach the market size of nearly USD 207.24 Billion by 2032 from USD 102.3 Billion in 2023 with a CAGR of 8.16% under the study period 2024 - 2032.

Active Pharmaceutical Ingredient Contract Development and Manufacturing Organizations (API CDMOs) specialize in the development and production of active pharmaceutical ingredients, which are the biologically active components in medications. These organizations offer services ranging from research and development to large-scale manufacturing, providing pharmaceutical companies with the expertise and infrastructure to bring drugs to market efficiently and in compliance with regulatory standards.

MARKET DYNAMICS

The Active Pharmaceutical Ingredient (API) Contract Development and Manufacturing Organization market is driven by factors such as the increasing complexity of drug development, outsourcing trends in the pharmaceutical industry, and the demand for cost-effective and flexible manufacturing solutions. Pharmaceutical companies are turning to API CDMOs to leverage their expertise in developing and producing high-quality active pharmaceutical ingredients. The rising number of biopharmaceuticals and specialty drugs, coupled with the need for specialized manufacturing capabilities, contributes to the market's growth. API CDMOs offer benefits such as reduced time-to-market, access to advanced technologies, and risk mitigation in drug development. The trend towards personalized medicine and the growing pipeline of innovative therapies also boost the demand for API CDMO services. Regulatory requirements and the need for compliance with Good Manufacturing Practice (GMP) standards drive pharmaceutical companies to partner with specialized API CDMOs, fostering innovation and efficiency in drug development.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of active pharmaceutical ingredient cdmo. The growth and trends of active pharmaceutical ingredient cdmo industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the active pharmaceutical ingredient cdmo market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

  • Traditional Active Pharmaceutical Ingredient (Traditional Api)
  • Highly Potent Active Pharmaceutical Ingredient (Hp-Api)
  • Antibody Drug Conjugate (Adc)
  • Others

By Synthesis

  • Synthetic
  • Biotech

By Drug

  • Innovative
  • Generics

By Workflow

  • Clinical
  • Commercial

By Application

  • Oncology
  • Hormonal
  • Glaucoma
  • Cardiovascular Disease
  • Diabetes
  • Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Active Pharmaceutical Ingredient CDMO market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Active Pharmaceutical Ingredient CDMO market include Cambrex Corporation, Recipharm AB, Thermo Fisher Scientific Inc. (Pantheon), CordenPharma International, Samsung Biologics, Lonza, Catalent, Inc., Siegfried Holding AG, Piramal Pharma Solutions, Boehringer Ingelheim International GmbH. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . ACTIVE PHARMACEUTICAL INGREDIENT CDMO - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Product
    • 3.7.2 Market Attractiveness Analysis By Synthesis
    • 3.7.3 Market Attractiveness Analysis By Drug
    • 3.7.4 Market Attractiveness Analysis By Workflow
    • 3.7.5 Market Attractiveness Analysis By Application
    • 3.7.6 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT CDMO MARKET ANALYSIS BY PRODUCT

  • 5.1 Overview by Product
  • 5.2 Historical and Forecast Data
  • 5.3 Analysis by Product
  • 5.4 Traditional Active Pharmaceutical Ingredient (Traditional API) Historic and Forecast Sales by Regions
  • 5.5 Highly Potent Active Pharmaceutical Ingredient (HP-API) Historic and Forecast Sales by Regions
  • 5.6 Antibody Drug Conjugate (ADC) Historic and Forecast Sales by Regions
  • 5.7 Others Historic and Forecast Sales by Regions

6 . GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT CDMO MARKET ANALYSIS BY SYNTHESIS

  • 6.1 Overview by Synthesis
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Synthesis
  • 6.4 Synthetic Historic and Forecast Sales by Regions
  • 6.5 Biotech Historic and Forecast Sales by Regions

7 . GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT CDMO MARKET ANALYSIS BY DRUG

  • 7.1 Overview by Drug
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by Drug
  • 7.4 Innovative Historic and Forecast Sales by Regions
  • 7.5 Generics Historic and Forecast Sales by Regions

8 . GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT CDMO MARKET ANALYSIS BY WORKFLOW

  • 8.1 Overview by Workflow
  • 8.2 Historical and Forecast Data
  • 8.3 Analysis by Workflow
  • 8.4 Clinical Historic and Forecast Sales by Regions
  • 8.5 Commercial Historic and Forecast Sales by Regions

9 . GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT CDMO MARKET ANALYSIS BY APPLICATION

  • 9.1 Overview by Application
  • 9.2 Historical and Forecast Data
  • 9.3 Analysis by Application
  • 9.4 Oncology Historic and Forecast Sales by Regions
  • 9.5 Hormonal Historic and Forecast Sales by Regions
  • 9.6 Glaucoma Historic and Forecast Sales by Regions
  • 9.7 Cardiovascular disease Historic and Forecast Sales by Regions
  • 9.8 Diabetes Historic and Forecast Sales by Regions
  • 9.9 Others Historic and Forecast Sales by Regions

10 . GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT CDMO MARKET ANALYSIS BY GEOGRAPHY

  • 10.1. Regional Outlook
  • 10.2. Introduction
  • 10.3. North America Sales Analysis
    • 10.3.1. Overview, Historic and Forecast Data Sales Analysis
    • 10.3.2. North America By Segment Sales Analysis
    • 10.3.3. North America By Country Sales Analysis
    • 10.3.4. United State Sales Analysis
    • 10.3.5. Canada Sales Analysis
    • 10.3.6. Mexico Sales Analysis
  • 10.4. Europe Sales Analysis
    • 10.4.1. Overview, Historic and Forecast Data Sales Analysis
    • 10.4.2. Europe by Segment Sales Analysis
    • 10.4.3. Europe by Country Sales Analysis
    • 10.4.4. United Kingdom Sales Analysis
    • 10.4.5. France Sales Analysis
    • 10.4.6. Germany Sales Analysis
    • 10.4.7. Italy Sales Analysis
    • 10.4.8. Russia Sales Analysis
    • 10.4.9. Rest Of Europe Sales Analysis
  • 10.5. Asia Pacific Sales Analysis
    • 10.5.1. Overview, Historic and Forecast Data Sales Analysis
    • 10.5.2. Asia Pacific by Segment Sales Analysis
    • 10.5.3. Asia Pacific by Country Sales Analysis
    • 10.5.4. China Sales Analysis
    • 10.5.5. India Sales Analysis
    • 10.5.6. Japan Sales Analysis
    • 10.5.7. South Korea Sales Analysis
    • 10.5.8. Australia Sales Analysis
    • 10.5.9. South East Asia Sales Analysis
    • 10.5.10. Rest Of Asia Pacific Sales Analysis
  • 10.6. Latin America Sales Analysis
    • 10.6.1. Overview, Historic and Forecast Data Sales Analysis
    • 10.6.2. Latin America by Segment Sales Analysis
    • 10.6.3. Latin America by Country Sales Analysis
    • 10.6.4. Brazil Sales Analysis
    • 10.6.5. Argentina Sales Analysis
    • 10.6.6. Peru Sales Analysis
    • 10.6.7. Chile Sales Analysis
    • 10.6.8. Rest of Latin America Sales Analysis
  • 10.7. Middle East & Africa Sales Analysis
    • 10.7.1. Overview, Historic and Forecast Data Sales Analysis
    • 10.7.2. Middle East & Africa by Segment Sales Analysis
    • 10.7.3. Middle East & Africa by Country Sales Analysis
    • 10.7.4. Saudi Arabia Sales Analysis
    • 10.7.5. UAE Sales Analysis
    • 10.7.6. Israel Sales Analysis
    • 10.7.7. South Africa Sales Analysis
    • 10.7.8. Rest Of Middle East And Africa Sales Analysis

11 . COMPETITIVE LANDSCAPE OF THE ACTIVE PHARMACEUTICAL INGREDIENT CDMO COMPANIES

  • 11.1. Active Pharmaceutical Ingredient Cdmo Market Competition
  • 11.2. Partnership/Collaboration/Agreement
  • 11.3. Merger And Acquisitions
  • 11.4. New Product Launch
  • 11.5. Other Developments

12 . COMPANY PROFILES OF ACTIVE PHARMACEUTICAL INGREDIENT CDMO INDUSTRY

  • 12.1. Company Share Analysis
  • 12.2. Market Concentration Rate
  • 12.3. Cambrex Corporation
    • 12.3.1. Company Overview
    • 12.3.2. Company Revenue
    • 12.3.3. Products
    • 12.3.4. Recent Developments
  • 12.4. Recipharm AB
    • 12.4.1. Company Overview
    • 12.4.2. Company Revenue
    • 12.4.3. Products
    • 12.4.4. Recent Developments
  • 12.5. Thermo Fisher Scientific Inc. (Pantheon)
    • 12.5.1. Company Overview
    • 12.5.2. Company Revenue
    • 12.5.3. Products
    • 12.5.4. Recent Developments
  • 12.6. CordenPharma International
    • 12.6.1. Company Overview
    • 12.6.2. Company Revenue
    • 12.6.3. Products
    • 12.6.4. Recent Developments
  • 12.7. Samsung Biologics
    • 12.7.1. Company Overview
    • 12.7.2. Company Revenue
    • 12.7.3. Products
    • 12.7.4. Recent Developments
  • 12.8. Lonza
    • 12.8.1. Company Overview
    • 12.8.2. Company Revenue
    • 12.8.3. Products
    • 12.8.4. Recent Developments
  • 12.9. Catalent Inc.
    • 12.9.1. Company Overview
    • 12.9.2. Company Revenue
    • 12.9.3. Products
    • 12.9.4. Recent Developments
  • 12.10. Siegfried Holding AG
    • 12.10.1. Company Overview
    • 12.10.2. Company Revenue
    • 12.10.3. Products
    • 12.10.4. Recent Developments
  • 12.11. Piramal Pharma Solutions
    • 12.11.1. Company Overview
    • 12.11.2. Company Revenue
    • 12.11.3. Products
    • 12.11.4. Recent Developments
  • 12.12. Boehringer Ingelheim International GmbH
    • 12.12.1. Company Overview
    • 12.12.2. Company Revenue
    • 12.12.3. Products
    • 12.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers : Impact Analysis
  • Restraints : Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis by Product (USD MN)
  • Traditional Active Pharmaceutical Ingredient (Traditional API) Market Sales by Geography (USD MN)
  • Highly Potent Active Pharmaceutical Ingredient (HP-API) Market Sales by Geography (USD MN)
  • Antibody Drug Conjugate (ADC) Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Analysis Market by Synthesis (USD MN)
  • Synthetic Market Sales by Geography (USD MN)
  • Biotech Market Sales by Geography (USD MN)
  • Analysis by Drug (USD MN)
  • Innovative Market Sales by Geography (USD MN)
  • Generics Market Sales by Geography (USD MN)
  • Analysis by Workflow (USD MN)
  • Clinical Market Sales by Geography (USD MN)
  • Commercial Market Sales by Geography (USD MN)
  • Analysis by Application (USD MN)
  • Oncology Market Sales by Geography (USD MN)
  • Hormonal Market Sales by Geography (USD MN)
  • Glaucoma Market Sales by Geography (USD MN)
  • Cardiovascular disease Market Sales by Geography (USD MN)
  • Diabetes Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Global Active Pharmaceutical Ingredient Cdmo Market Sales by Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United State Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate by Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Active Pharmaceutical Ingredient Cdmo Report
  • Market Research Process
  • Market Research Methodology
  • Global Active Pharmaceutical Ingredient Cdmo Market Size, by Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis by Product
  • Market Attractiveness Analysis by Synthesis
  • Market Attractiveness Analysis by Drug
  • Market Attractiveness Analysis by Workflow
  • Market Attractiveness Analysis by Application
  • Market Attractiveness Analysis by Region
  • Value Chain Analysis
  • Global Market Analysis by Product (USD MN)
  • Traditional Active Pharmaceutical Ingredient (Traditional API) Market Sales by Geography (USD MN)
  • Highly Potent Active Pharmaceutical Ingredient (HP-API) Market Sales by Geography (USD MN)
  • Antibody Drug Conjugate (ADC) Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Global Market Analysis by Synthesis (USD MN)
  • Synthetic Market Sales by Geography (USD MN)
  • Biotech Market Sales by Geography (USD MN)
  • Global Market Analysis by Drug (USD MN)
  • Innovative Market Sales by Geography (USD MN)
  • Generics Market Sales by Geography (USD MN)
  • Global Market Analysis by Workflow (USD MN)
  • Clinical Market Sales by Geography (USD MN)
  • Commercial Market Sales by Geography (USD MN)
  • Global Market Analysis by Application (USD MN)
  • Oncology Market Sales by Geography (USD MN)
  • Hormonal Market Sales by Geography (USD MN)
  • Glaucoma Market Sales by Geography (USD MN)
  • Cardiovascular disease Market Sales by Geography (USD MN)
  • Diabetes Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.